Research Report

Author

研究部 (Research Team)
輝立証券

Phone: (852)22776555  
Email Enquiry For Research Report and Business enquiry

New China Insurance (1336.HK) - Stable growth of market shares with strong rebound of profits in future

Wednesday, January 16, 2013 Views11856
New China Insurance(1336)
Recommendation on  16 January 2013
Recommendation Buy
Price on Recommendation Date $32.150
Target Price $37.080

Company Introduction

New China Insurance (NCI or the Group) was founded in Beijing in Sep 1996, which is one of the largest insurers in China now. NCI were listed in A+H Shares in 2011, and currently it owns over 50,000 employees and 1,500 branches nationwide. According to the records of premiums incomes from CIRC, as at the end of Nov 2012, NCI was the third largest Life insurer in China.

Summary

-According to the data from CIRC, the premium incomes of NCI achieved to RMB92.219 billion, increased slightly by 3.89% y-y in Nov 2012, which was better than the performance of the industry with the growth rate of 3.54% during the same period although the Group's growth rate appeared to decrease month by month;

-According to 3Q report, the Group's total assets increased significantly by 24.5% to RMB481.358 billion compared to the end of 2011, equivalent to BVPS of RMB11.05, 10.1% higher than that of 2011;

-Accumulated net profits of NCI recorded to RMB2.324 billion, raised 2.42% y-y, better than the peers, while China Life recorded the loss of RMB2.2 billion and CPIC's net profits dropped 59% y-y approximately;

-However, we noted one of main reasons that NCI gained the better profit performance was the realization of deferred tax of assets with the amount of RMB444 million. Ignoring such accounting treatment, NCI's profits before tax would decrease by 26.41% y-y, consistent with market trend;

-On the other hand, there was a news that CSRC would approve domestic insurance companies to open retail fund management business in future, which may cause insurers` incomes to go up, and investment incomes would rebound obviously benefited from improvement of market environment. Therefore we expect NCI's profits would increase significantly in the next two years. The Group's net profits would rise 10% y-y approximately to RMB3.081 in 2012 with the EPS of RMB0.99;

-In summary, we hold optimistic views for NCI's future performance, and estimate the 12-month target price to HK$37.08, around 15.30% higher than the latest closing price, equivalent to 2013P/E18.7x and P/B2.3x respectively. Maintain Buy rating.

Click Here for PDF format...

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us